Safety of Chronic Anticoagulation Therapy After Endovascular Abdominal Aneurysm Repair (EVAR)  by De Rango, P. et al.
Safety of Chronic Anticoagulation Therapy After Endovascular Abdominal
Aneurysm Repair (EVAR) 5
P. De Rango a,*, F. Verzini a, G. Parlani a, E. Cieri a, G. Simonte a, L. Farchioni a, G. Isernia a, P. Cao b
a Unit of Vascular and Endovascular Surgery, Hospital S. Maria Misericordia, Perugia, Italy
b Unit of Vascular Surgery, Dept. of Cardiosciences, Hospital S. Camillo e Forlanini, Rome, Italy5 Th
Budape
please
* Cor
Univers
Fratte,
E-ma
1078
Surgery
http:WHAT THIS PAPER ADDS
Knowledge of the negative impact (higher risk of loss of stentgraft sealing, reintervention, and conversion) of
chronic anticoagulation on early and late outcomes of endovascular aortic repair (EVAR) shown in this study
should inform the future decision-making approach for patients with both abdominal aortic aneurysms (AAA)
and cardiac disease, who may require prolonged anticoagulation treatment.Objective: Current data supporting the effect of anticoagulation drug use on aneurysm sealing and the durability
of endovascular abdominal aneurysm repair (EVAR) are conﬂicting. This study assessed the safety of chronic
anticoagulation therapy after EVAR.
Methods: Records of 1409 consecutive patients having elective EVAR during 1997e2011 who were prospectively
followed were reviewed. Survival, reintervention, conversion, and endoleak rates were analyzed in patients with
and without chronic anticoagulants. Cox proportional hazards models were used to estimate the effect of
anticoagulation therapy on outcomes.
Results: One-hundred and three (7.3%) patients were on chronic anticoagulation drugs (80 on vitamin K
antagonists) at the time of EVAR. An additional 46 patients started on anticoagulants after repair were identiﬁed.
Patients on chronic anticoagulation therapy at repair (mean age 73.6 years; 91 males) had more frequent cardiac
disease (74.8% vs. 44.2%; p < 00001), but no other differences in demographic and major baseline comorbidities
with respect to the others. At baseline, mean abdominal aortic aneurysm (AAA) diameter was 56.43 mm vs.
54.65 mm (p ¼ .076) and aortic neck length 26.54 mm vs. 25.21 mm (p ¼ .26) in patients with and without
anticoagulants, respectively. At 5 years, freedom from endoleak rates were 55.5% vs. 69.9% (p < .0001), and
freedom from reintervention/conversion rates were 69.4% vs. 82.4% (p < .0001) in patients with (including those
with delayed drug use) and without chronic anticoagulants, respectively. Controlling for covariates with the Cox
regression method, at a mean follow-up of 64.3  45.2 months after EVAR, use of anticoagulation drugs was
independently associated with an increased risk of endoleak (odds ratio, OR 1.6; 95% conﬁdence interval, CI:
1.23e2.07; p < .0001) and reintervention or late conversion rates (OR 1.8; 95% CI: 1.31e2.48; p < .0001).
Conclusions: The safety of anticoagulation therapy after EVAR is debatable. Chronic anticoagulation drug use
risks exposure to a poor long-term outcome. A critical and balanced decision-making approach should be applied
to patients with AAA and cardiac disease who may require prolonged anticoagulation treatment.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 31 August 2013, Accepted 2 December 2013, Available online 18 January 2014
Keywords: Anticoagulation, Warfarin, Endovascular abdominal aortic aneurysm repair, EVAR, Reintervention,
Conversion, Endoleak, Chronic anticoagulantVitamin K antagonists (VKAs) and heparins have been used
as an effective therapy to prevent the thromboembolice paper was presented at the 2013 ESVS Annual Meeting, in
st.
To access continuing medical education questions on this paper,
go to www.vasculareducation.com and click on ‘CME’
responding author. P. De Rango, Vascular and Endovascular Unit,
ity of Perugia, Hospital S. Maria Misericordia, Loc. S. Andrea delle
06134 Perugia, Italy.
il address: plderango@gmail.com (P. De Rango).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.12.009complications of atrial ﬁbrillation (AF), valvular heart dis-
ease (VHD), and venous thromboembolism (VTE). The use of
chronic anticoagulation drugs is expected to further in-
crease in the Western world because of the aging popula-
tion and the introduction of new oral anticoagulants with
safer proﬁles.1 However, chronic anticoagulant therapy is
extremely challenging in clinical practice: the target level of
anticoagulation involves a balance between prevention of
ischemic events and avoidance of hemorrhagic complica-
tions.2 The risk/beneﬁt ratio should be estimated in each
individual patient and is particularly important for elderly
patients with AF. Speciﬁcally, in old patients with abdominal
aortic aneurysms (AAA) and cardiac disease (often requiring
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repair (EVAR) is usually preferred to open surgery to mini-
mize the operative complications and hemorrhagic risks of
open surgery. Therapeutic doses of anticoagulants could
theoretically prevent spontaneous aneurysm sac throm-
bosis and increase the incidence of endoleak and, therefore,
of EVAR failure. Nevertheless, the effect of the patient
coagulation status on the success of endovascular aneurysm
exclusion in the early stages, and particularly in the long
term, is a reason for concern. This remains unresolved in the
current literature because studies that speciﬁcally analyze
the effect of chronic anticoagulation on outcomes of EVAR
are limited and the results discordant.3e8
The aim of this study was to analyze early and late out-
comes of EVAR patients on chronic anticoagulation therapy
in a large series of patients.METHODS
From April 1997 to December 2011, all patients with
infrarenal AAA who underwent EVAR were prospectively
entered into a database. Recorded data included de-
mographics, clinical comorbidities, baseline drug use
including anticoagulation methods, aneurysm morphology
details, EVAR devices, intraoperative details, and follow-up
outcomes. Patients treated as an emergency for AAA
rupture and those receiving fenestrated stentgrafts were
excluded from the present study that focused on 1409
patients receiving anticoagulant therapy or not. The
collected data were reviewed to investigate whether the
use of chronic anticoagulation drugs before EVAR affected
EVAR outcome. Patients were divided into two groups:
those on chronic anticoagulation therapy (VKAs or heparins)
and those not, at the time of EVAR. However, the database
only included drug data at the time of operation and data
were not collected on the use of anticoagulants during
follow-up after EVAR. For the purpose of this study, to
further investigate the potential effect of chronic antico-
agulants on late outcomes of EVAR, patients were con-
tacted by telephone and speciﬁcally questioned about the
introduction of anticoagulation therapy following EVAR. The
overall group of patients with long-standing (on therapy at
the time of EVAR) and delayed (started after discharge)
anticoagulation treatment was separately assessed.
Patients on anticoagulants and those not, were
compared for perioperative variables and outcomes at 60
months. The primary outcomes were survival and the need
for reintervention. Secondary outcomes were aneurysm-
related survival, need for conversion, and endoleak
incidence.
Patients received intraoperative intravenous unfractio-
nated heparin (100 U/kg). EVAR was performed by a
dedicated team under general or local anesthesia using
different device models depending on the aorto-iliac
morphology, stentgraft availability, and operator prefer-
ences. There were n ¼ 610 (43.3%) Zenith (Cook Inc.,
Blooomington, IN, USA); n ¼ 235 (16.7%) AneuRx (Med-
tronic Vascular, Santa Rosa, CA, USA); n ¼ 167 (11.8%)Talent (Medtronic Vascular, Santa Rosa, CA, USA); n ¼ 71
(5.0%) Endurant (Medtronic Vascular, Santa Rosa, CA,
USA); n ¼ 232 (16.5%) Excluder (Gore & Associates, Inc,
Flagstaff, AZ, USA); n ¼ 35 (2.5%) Fortron (Johnson &
Johnson e Cordis Corporation, Bridgewater, NJ, USA);
n ¼ 53 (3.8%) Anaconda (Terumo Vascutek, Inchinnan
Renfrewshire, UK), and n ¼ 6 (0.4%) others.
After EVAR, patients were scheduled for serial follow-up
including clinical evaluation and imaging with duplex ul-
trasound and computed tomography angiography (CTA)
scan at 1, 6, and 12 months, and yearly thereafter. Use of
CTA was less frequently applied in the most recent years.
A vascular dedicated digital workstation (TeraRecon
Aquarius Workstation, Terarecon, Foster City, CA, USA) was
used for CTA-scan imaging analysis and three-dimensional
(3D) reconstructions. Endoleaks and complications were
recorded and classiﬁed according to Standardized Report-
ing Practices in Vascular Surgery.9 Reinterventions were
performed at the discretion of the attending surgeon, but,
in general, treatment was applied when AAA showed type
I/III endoleak or persisting type II endoleak/endotension
associated with a diameter increase >5 mm after EVAR or
in the presence of major complications (migration, dis-
connections, limb occlusion, rupture). The type of treat-
ment was individualized to aneurysm anatomy and
endoleak source.10
Because of the retrospective analysis of prospectively
collected data, there was no requirement for local ethical
committee approval.Statistical analysis
Descriptive statistics for categorical variables were pre-
sented as relative frequencies (percentages); chi-square test
or Fisher exact test, when appropriate, were used to eval-
uate univariate differences between the chronic anticoag-
ulant (VKAs or heparin) and non-anticoagulant groups.
Continuous variables were expressed as mean with stan-
dard errors (SE) and ranges. KaplaneMeier survival esti-
mates were used to determine survival, aneurysm-related
survival, and freedom from reintervention, conversion, and
endoleak in patients with and without chronic anti-
coagulation therapy. Log-rank test was used to assess dif-
ference between groups.
The odds ratio (OR) and 95% conﬁdence intervals (CIs) for
different outcomes were estimated with multivariate ana-
lyses using Cox regression models. Backward selection was
used to evaluate time-to-event effects of chronic anti-
coagulation and the development of need for reintervention
and endoleak occurrence while controlling for the following
confounders: age, gender, diabetes, hypertension, cardiac
disease (CAD), peripheral artery disease (PAD), chronic
obstructive pulmonary disease (COPD), aneurysm diameter,
intraluminal thrombus, and anticoagulation treatment.
Findings were considered statistically signiﬁcant if the
resulting p value was less than .05. SPSS for Mac/OS version
20.0 (SPSS Inc. Chicago, IL, USA) was used for all statistical
analyses.
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One-hundred and three (7.3%) patients were on chronic
anticoagulation drugs at the time of repair. Mean age was
73.57 þ 7.2 years and 91 (88.3%) were males. Eighty were
on VKAs and the remaining 23 on heparins. No new oral
anticoagulants were used. There were no major differ-
ences in baseline morphology or clinical characteristics of
patients with and without anticoagulants at the time of
repair, with the exception of cardiac disease which was
more frequent in the group on anticoagulation drugs:
74.8% vs. 44.2%, p < .0001 (Table 1). Speciﬁcally, mean
AAA diameter (56.43 mm vs. 54.65 mm; p ¼ .076) and
aortic neck length (26.54 mm vs. 25.21 mm; p ¼ .26) were
comparable in patients with and without chronic anti-
coagulation therapy.
Distribution of anticoagulation treatment among
different device models is shown in Table 2.
Perioperative mortality was 0.9% without signiﬁcant dif-
ferences among patients with and without anticoagulants
(p ¼ .62). Rates of immediate endoleak (at procedure
completion angiography or at discharge duplex scan) were
detected in 25/103 (24.3%) of the anticoagulated group vs.
203/1306 (15.5%) of the others (p ¼ .026). The overall rate
of early endoleaks detected at 30 days was signiﬁcantly
higher in the anticoagulated group: 28.2% vs. 17.6%;
p ¼ .012 (Table 1).Table 1. Baseline characteristics and demographics of patients with an
Anticoagulant
@repair
(n ¼ 103)
No anticoa
@repair (n
N % N
Age (y), mean  SD 73.57  7.2 72.86  7
Males 91 88.3 1196
Hypertension 83 80.6 998
CADc 77 74.8 577
Obesity 13 12.6 158
PAD 19 18.4 161
Diabetes 19 18.4 156
COPD 51 49.5 645
Chronic renal failure 17 16.5 184
Cerebrovascular disease 14 13.6 179
Vitamin K antagonists 80 e
Antiplateletsc 7 6.8 701
AAA diameter, mean þ SD 56.43  9.8 54.65  9
Neck length, mean þ SD 26.5  12.8 25.2  10
Neck diameter, mean þ SD 24.16  3.1 23.45  3
Circumferential calciﬁcation 2 1.9 18
Intraluminal aortic thrombus 53 51.5 642
Perioperative death 0 13
Immediate endoleakc 25 24.3 203
Immediate type II endoleak 18 17.5 151
30-day endoleakc 29 28.2 230
CAD ¼ cardiac disease; PAD ¼ peripheral artery disease; COPD ¼
aneurysm.Antiplatelets including aspirin, ticlopidine, clopidogrel, and o
a p-value displayed for comparison between patients anticoagulated a
b 149 patients with any anticoagulation (at the time of repair or af
characteristics.
c Signiﬁcant differences.Patients on anticoagulants had lower 5-year late all-cause
survival rates compared with those without anticoagulation
treatment: 65.5% vs. 70.5%; p ¼ .045 (Fig. 1). However,
aneurysm-related survival was comparable in the two
groups (at 5 years: 98.2% vs. 98.5%; p ¼ .42). Five-year
freedom from any reintervention (69.3% vs. 84.5%;
p < .0001) and from any reintervention or late conversion
(68.5% vs. 81.9%; p < .0001) were signiﬁcantly lower in
patients using anticoagulants. Freedom rates from reinter-
vention speciﬁcally focused on type II endoleak were also
signiﬁcantly lower (p ¼ .048).
Occurrence of any endoleak was higher in patients on
anticoagulation therapy: 5-year freedom rates were 57.5%
vs. 69.2% (p ¼ .005) in patients with and without anti-
coagulation treatment, respectively. However, freedom
from type II endoleak rates were not signiﬁcantly lower:
71.6% vs 77.3%; p ¼ .06.
An additional 46 patients started on anticoagulant ther-
apy after repair were identiﬁed during mean follow-up of
64.3  45.2 months. According to phone interview with
patients, the most common indication was AF but full
ascertainment of reasons and underlying cardiac or other
diseases could not be conﬁrmed. The main characteristics of
the whole group of 149 early and delayed anticoagulated
patients are shown in Tables 1 and 2. When the overall
group of anticoagulated patients was analyzed, 5-year ratesd without anticoagulant therapy.
gulant
¼ 1306)
p-valuea Anticoagulant
(repair or after) (n ¼ 149)b
% N (%)
.7 .37 73.22  6.7
91.6 .23 133 (89.3)
76.4 .39 119 (79.9)
44.2 <.0001 100 (67.1)c
12.1 .87 23 (15.4)
12.3 .09 23 (15.4)
11.9 .06 24 (16.1)
49.4 .99 75 (50.3)
14.1 .47 21 (14.1)
13.7 .99 20 (13.4)
e e 126
53.7 <.0001
.7 .076 55.20  9.2
.6 .26 26.7  12.0
.6 .06 23.8  2.9
1.4 .65 2 (1.3)
49.2 .68 80 (53.7)
1.0 .62
15.5 .026
11.6 .083
17.6 .012
chronic obstructive pulmonary disease; AAA ¼ abdominal aortic
thers.
nd not at the time of repair.
ter) were compared with the remaining 1260 for distribution of
Table 2. Anticoagulant use distribution by device models.
N Anticoagulant
@repair (n ¼ 103)
No anticoagulant
@repair (n ¼ 1306)
Any anticoagulant
(repair or after) (n ¼ 149)
p Value
N (%) N (%) p-value N (%)
Zenith Cook 610 52 (50.7) 558 (42.7) .15 74 (49.7) 0.12
Excluder Gore 232 14 (13.6) 218 (16.7) .49 24 (16.1) 0.99
Endurant Medtronic 71 5 (4.9) 66 (5.1) .99 6 (4.0) 0.69
Talent Medtronic 167 14 (13.6) 153 (11.7) .53 16 (10.7) 0.79
AneuRx Medtronic 235 14 (13.6) 221 (16.9) .49 21 (14.1) 0.42
Anaconda Vascutek 53 2 (1.9) 51 (3.9) .43 3 (2.0) 0.36
Fortron Cordis 35 1 (1.0) 34 (1.0) .51 4 (2.7) 0.78
Others 6
New devicesa 879 68 (66) 811 (62.1) .46 95 (63.8) 0.79
a AneuRx, Fortron, and Excluder and Anaconda 1st generation, were excluded.
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p < .0001), reintervention or late conversion (69.4% vs.
82.4%; p < .0001; Fig. 2), and late conversion (94.1% vs.
96.1%; p ¼ .036) were signiﬁcantly lower in the group of
patients on anticoagulants. Freedom rates from reinter-
vention for type II endoleak were 89.5% vs. 95.3%
(p ¼ .008).
Five-year freedom from endoleak rates (55.5% vs. 69.9%;
p < .0001) (Fig. 3) or type II endoleak rates (67.6% vs.Figure 1. Late all-cause survival in patients on anticoagulants or
not at time of endovascular aortic aneurysm repair (EVAR).78.0%; p ¼ .002) were also signiﬁcantly lower in anti-
coagulated patients.
Cox regression analysis identiﬁed anticoagulation therapy
as an independent positive predictor of reintervention or
late conversion (OR 1.8; 95% CI: 1.31e2.48; p < .0001)
together with large AAA diameter and coronary disease.
Diabetes was identiﬁed as a negative predictor (Table 3).
Anticoagulation therapy was also an independent predictor
of any endoleak, OR 1.6; 95% CI: 1.23e2.07; p < .0001
(Table 3), except type II endoleak alone.Figure 2. Freedom from late reintervention or conversion after
aortic aneurysm repair (EVAR) in patients on anticoagulants or not.
Figure 3. Freedom from any endoleak after aortic aneurysm repair
(EVAR) in patients on anticoagulants or not.
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Even though the proportion of EVAR patients on antico-
agulants represents a minority (<20%) of the overall EVAR
population,3e6 concerns about the use of warfarin in these
patients is of relevance because EVAR outcomes can be
largely inﬂuenced by an individual based decision-making
approach. Furthermore, it is expected that the number of
patients with AF (requiring chronic anticoagulation) and
AAA will increase in the near future because of the aging
population.1 Indeed, anticoagulants are among the fewTable 3. Cox regression analysis.
Dependent variable Covariate OR 95% CI p-value
Late reintervention
or conversion
Anticoagulant 1.80 1.31e2.48 <.0001
Cardiac disease 1.30 1.01e1.68 .041
Aneurysm
diameter
1.02 1.01e1.03 .001
Diabetes 0.44 0.26e0.75 .002
Endoleak Anticoagulant 1.60 1.23e2.07 <.0001
Age 1.02 1.01e1.03 .002
Aneurysm
diameter
1.01 1.01e1.02 .019
Peripheral
disease
0.73 0.53e0.99 .048drugs with known effects on outcomes of AAA. In the last
few years there has been an increasing interest in the op-
tion to pharmacologically change the natural history and
outcome of AAA. Although statins, non-steroidal anti-in-
ﬂammatory drugs (NSAIDs), macrolides, antihypertensive,
and beta-blockers have been scrutinized, there is no
consistent pattern of their pharmacological inﬂuence on
aneurysmal expansion rate and rupture prevention.11,12
However, there are data supporting the concurrent use of
chronic anticoagulants negatively inﬂuencing durability of
EVAR. Anticoagulated patients require almost twice as
many reinterventions to maintain aneurysm sac exclusion
at a mean follow-up of 64.3 months after endovascular
repair, based on the results of this study. Furthermore,
despite the higher number of repeated procedures/rein-
terventions after EVAR (freedom from reintervention rates,
71.7% vs. 84.9% in anticoagulated patients vs. not) repair
more often resulted in failure, with a higher risk of late
conversion to open surgery (p ¼ .036). As in most anti-
coagulated patients the reason for choosing EVAR is likely
to be to avoid open surgery for coexistent cardiac disease,
the delayed need for conversion to open surgery after
EVAR failure represents a considerable challenge. However,
the results of this study should be interpreted with caution
because no random assignment was used and the strength
of ﬁndings was limited by the retrospective analysis with
inherent risk of bias.
The negative effect of chronic anticoagulation on the
outcome of EVAR is a relevant factor to be considered in
the best management of care when counseling patients
requiring treatment for both their cardiac disease and AAA.
Because of the conﬂicting effects of anticoagulation drugs
and EVAR on AAA repair it may be reasonable to avoid
combining the two treatments in the same patient and to
select EVAR with drug alternatives to anticoagulants in
EVAR candidates or continue to anticoagulate patients
while using open surgery for treatment of the aneurysm.
The proportion of patients on anticoagulants (10.6%) at
the time of repair or after in this study was limited and
inferior to that shown in other series of EVAR patients. In
US series, percentages of 15e18% were reported.3e6 This
variability might be a result of underestimation of true rates
because of study limitations, but it can reﬂect different
national strategies to application of chronic anticoagulation
therapy. Today in Western countries, AF is the most com-
mon indication for the use of chronic anticoagulants.
Despite current AF guidelines, both European and AHA
suggest a rather liberal use of anticoagulant prophylaxis to
prevent ischemic stroke and mortality.13e16 Not all AF pa-
tients are on chronic anticoagulation drugs, for a variety of
reasons, but mainly the balance and monitoring of hem-
orrhagic risks. Furthermore, it is known that in many pa-
tients on chronic warfarin therapy, the proper therapeutic
target range of anticoagulation is not always main-
tained1721 and patients are often over-anticoagulated or
under-anticoagulated despite chronic drug administration
without intentional therapeutic interruptions (“holds”).2
Reviews of studies reporting warfarin-treated patients
Table 4. Literature studies on anticoagulant and EVAR.
Author year EVAR
N
Follow-up, mean Anticoagulant
N (%)
No anticoagulant
N (%)
Fairman 20022 232 18 months 36 (15.5) 196
30-day endoleak 7 (19.4) 36 (18.4)
Delayed endoleak 2 (5.6) 2 (1)
Any endoleak 9 (25) 38 (19.3)
Sac shrinkage 12 months (17.5%) (7.6%)
Biebl 20055 182 16.3 months 21 (11.5) 161
30-day endoleak 5 (23.8) 17 (10.6)
Delayed endoleak 0 17 (10.6)
Any endoleak 5 (23.8) 34 (21.1)
Conversion 0 3 (1.9)
Sac shrinkage 8 (38.1) 79 (49.1)
Sac stabilization 13 (61.9) 77 (47.8)
Bobadilla 20104 127 2.14 years 24 (18.9) 103
Any endoleak 13 (54.2) 25 (24.3)
Volume change (þ29.3%) (18.9%)
Reintervention 6 (46) 8 (32)
Conversion 3 (12.5) 2 (1.9)
Johnson 20133 363 29 months 68 (18.7) 295
Any endoleak 11 (16.2%) 34 (11.5)
Sac expansion 5 (7.4) 21 (7.1)
Rupture 0 2 (0.7)
Reintervention 10 (14.7) 33 (11.2)
Conversion 3 (4.4) 5 (1.7)
Deaths 7 (10.3) 35 (11.9)
Total 904 64 months 149 755
Present study 1409 103 at repair (7.3) 1306
149 overall (10.6) 1260
EVAR ¼ endovascular abdominal aneurysm repair.
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time within the therapeutic international normalized ratio
(INR)17e19 mainly because of inadequate compliance that
the patient does not recall or does not declare.2,17,18 Also, it
has been noted that the occurrence of a low INR often
depends on the indication for anticoagulant therapy, with
the highest risk in patients who used anticoagulants as
prophylaxis and the lowest risk in patients with mechanical
heart valves.19 Even though it is likely that with the newer
anticoagulation agents with safer proﬁles and lower moni-
toring requirements (e.g. dabigatran, rivaroxaban, apixaban)
patients’ adherence and stabilization of blood anti-
coagulation levels can be improved,16,22 the great amount
of time outside the target therapeutic range in many
currently anticoagulated patients may question the abso-
lute necessity of anticoagulation drugs in these settings.21,22
This is speciﬁc in those patients with cardiac dysrhythmia
and AAA suitable for EVAR, which might be selected as a
ﬁrst therapeutic aneurysm repair choice. In some older
patients, especially those at higher risk of cerebral hemor-
rhage (e.g. severe hypertension) and with lower thrombo-
embolic risk, use of aspirin (ASA) rather than oral
anticoagulants might still be a valid option. However, the
decision should be cautious and balanced as discontinua-
tion of anticoagulants may not be advisable in many other
patients at higher thromboembolic risk given their severe
heart disease.A number of studies have suggested that chronic anti-
coagulation drugs might contribute to type II endoleak
occurrence or persistence because of interference with the
clotting of blood ﬂowing into the excluded aneurysm sac
from collateral vessels.4e6 Nevertheless, it is likely that
anticoagulation drugs could impact any type of endoleak
occurrence because of the negative effect of achieving
adequate sealing between the stentgraft and the aneu-
rysmal sac, regardless of the source of intrasac blood ﬂow.
In this series there was a signiﬁcant difference in overall
endoleak rates in anticoagulated and non-anticoagulated
patients: 55.5% vs. 69.9% freedom rates (p < .0001).
Similarly, Bobadilla et al. found an any-type endoleak rate of
13/24 in the warfarin group and 25/103 in the antiplatelet
group of EVAR patients.4
Results of this study suggesting a negative outcome for
EVAR in anticoagulated patients do not totally agree with
those of other series.3,6 The most recent publication by
Johnson et al. reported on 68 EVAR patients with a 29
month follow-up and showed composite reintervention and
death rates similar to those of 295 non-anticoagulated
EVAR patients.3 However, there is only limited and mostly
conﬂicting published literature on the issue.4,5 It is likely
that the variability is related to the small number of the
overall population in each study as summarized in Table 4.
Although there may be more information available in EVAR
registries on this topic, underestimation of true rates and
302 P. De Rango et al.variability in national strategies are likely to inﬂuence the
ﬁndings. Our large series of 1409 EVAR patients could
provide stronger data and improve the knowledge on an-
ticoagulants in EVAR patients.
Although this study provides the largest series on the use
of anticoagulants in EVAR patients, limitations include
retrospective analysis (with related risk of bias) and the
“presumptive” use of chronic anticoagulation because of
the lack of ascertainment of therapeutic range (INR be-
tween 2.0 and 3.0) for each patient. Patient adherence to
therapy is another issue. Furthermore, the accuracy of
ascertainment of new introduction of anticoagulation drugs
after discharge by telephone interview with patients may be
limited. Accordingly, the most common indication for
starting anticoagulants after EVAR was AF but full ascer-
tainment of reasons and underlying cardiac or other dis-
eases could not be detailed. Finally, analysis of antiplatelet
drugs and type in the non-anticoagulated group of patients
was not performed.
Conclusions
Medical therapy can affect the outcome of aneurysm repair
and should be carefully managed during the perioperative
period and in the years following operation to optimize the
effect of invasive approach. The safety of anticoagulation
therapy after EVAR may be debatable. Chronic anti-
coagulation drug use can lead to a poor long-term outcome.
A critical and balanced decision-making approach should be
applied to patients with AAA and cardiac disease, who
would also require prolonged anticoagulation treatment.
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